Quadrivalent meningococcal (MenACWY-TT) conjugate vaccine or a fourth dose of H. influenzae–N. meningitidis C/Y conjugate vaccine (HibMenCY-TT) is immunogenic in toddlers who previously received three doses of HibMenCY-TT in infancy  by Leonardi, Michael et al.
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Background:  Immunogenicity  and  safety  of a single  dose of  MenACWY-TT  or  a fourth  dose  of  HibMenCY-TT
were  evaluated  in the  second  year  of  life  in  HibMenCY-TT-primed  toddlers.
Methods: Healthy  infants  were randomized  (5:1) and primed  at 2, 4 and  6 months  of  age with  HibMenCY-
TT  and  diphtheria–tetanus–acellular  pertussis–hepatitis  B-inactivated  poliovirus  (DTaP–HBV–IPV)
vaccine; or  Hib-TT  and  DTaP–HBV–IPV  (control).  Recipients  of  HibMenCY-TT  + DTaP–HBV–IPV  were
re-randomized  (2:2:1)  to receive  MenACWY-TT  at 12–15  months  and  DTaP  at  15–18  months;  MenACWY-
TT  co-administered  with  DTaP  at 15–18  months;  or  HibMenCY-TT  at 12–15 months  and  DTaP  at
15–18  months.  Controls  received  DTaP  only  at 15–18  months  due  to Hib  conjugate  vaccine  shortage.
Serum  bactericidal  activity  using  human  complement  (hSBA)  and  safety  were  assessed  one  month  afteronjugate vaccineerum bactericidal activity
ibMenCY
meningococcal  vaccination.
Results:  After  vaccination  with  MenACWY-TT  at 12–15  months  or MenACWY-TT  + DTaP  at 15–18  months,
all  subjects  previously  primed  for  serogroups  C/Y had  hSBA  ≥1:8  for these  serogroups.  At least  96.1%  also
had hSBA  ≥1:8 for serogroups  A/W.  All  subjects  in the HibMenCY-TT  group  had  hSBA  ≥1:8  for  serogroups
C/Y.  All  pre-deﬁned  statistical  criteria  for meningococcal  immunogenicity  were  satisﬁed.  All vaccination
regimens  had  acceptable  safety  proﬁles.
Abbreviations: 95% CI, 95 percent conﬁdence interval; ACIP, Advisory Committee on Immunization Practices; AE, adverse event; ATP, according-to-protocol; Coad, co-
dministration treatment group who  received MenACWY-TT + DTaP at the fourth dose visit (15/18 months of age); DTaP, combined diphtheria–tetanus–acellular pertussis
accine; DTaP–HBV–IPV, combined diphtheria–tetanus–acellular pertussis–hepatitis B-inactivated poliovirus vaccine; GMT, geometric mean antibody titers; Hib-MenCY-
T,  meningococcal serogroup C and Y conjugate vaccine combined with Haemophilus inﬂuenzae type b conjugate vaccine; Hib-TT, Haemophilus inﬂuenzae type b conjugate
accine; hSBA, serum bactericidal activity using human complement source; IMD, invasive meningococcal disease; MenACWY-DT, quadrivalent serogroups A, C, W and Y
onjugate vaccine with all serogroups conjugated to the diphtheria toxoid carrier protein; MenACWY-CRM197, quadrivalent serogroups A, C, W and Y conjugate vaccine with
ll  serogroups conjugated to CRM-197 (mutant diphtheria toxoid); MenACWY-TT, quadrivalent serogroups A, C, W and Y conjugate vaccine with all serogroups conjugated
o  the tetanus toxoid carrier protein; SAE, serious adverse event; PRN, pertactin; TT, tetanus toxoid; US, United States.
∗ Corresponding author. Tel.: +1 843 797 5600; fax: +1 843 572 4872.
E-mail address: mikeyleonardi@yahoo.com (M.  Leonardi).
ttp://dx.doi.org/10.1016/j.vaccine.2014.08.027
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Conclusion:  Children  primed  with  three  doses  of  HibMenCY-TT  who  then  received  a single  dose  of
MenACWY-TT or  a fourth  dose  of HibMenCY-TT  had  robust  increases  in hSBA  titers  for serogroups  C/Y.
These data  provide  support  that MenACWY-TT,  given  with  or without  the  fourth  scheduled  dose of  DTaP
could be  administered  as  an  alternative  to a fourth  dose  of HibMenCY-TT  in the  second  year  of  life.
This  study  (110870/110871)  is  registered  at www.clinicaltrials.gov  NCT00614614.
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. Introduction
Invasive Neisseria meningitidis infection causes severe disease
ith approximately 10% mortality even when appropriate antibi-
tics and supportive therapy are administered [1]. In the United
tates (US) the majority of invasive meningococcal disease (IMD)
s caused by serogroups B, C and Y [2]. While serogroups A and
 are more rarely detected in the US, they are important causes
f disease outbreaks in many regions worldwide, including Latin
merica [3–6]. Infants <1 year of age have the highest incidence
f IMD  (5.38 cases per 100,000 population; 1998–2007 US data)
2]. Therefore, in order to impact IMD  in US infants and children,
eningococcal conjugate vaccines need to be effective from early
ges [7].
The meningococcal serogroups C/Y vaccine, combined with
aemophilus inﬂuenzae type-b (HibMenCY-TT, MenHibrixTM, Glax-
SmithKline Vaccines), is approved in the US as a four-dose series
n infants. HibMenCY-TT is recommended by the Advisory Commit-
ee on Immunization Practices (ACIP) for use in infants and children
t increased risk for IMD  such as those with complement deﬁcien-
ies or asplenia including sickle cell disease, and may  be used as an
lternative for routine vaccination against Hib [8]. Immunogenicity
nd safety of HibMenCY-TT was demonstrated in clinical trials con-
ucted in infants and toddlers [9–16]. The quadrivalent serogroups
/C/W and Y meningococcal conjugate vaccine MenACWY-CRM197
MenveoTM, Novartis) is also approved in the US as a four-dose
eries in infants, and MenactraTM (MenACWY-DT, Sanoﬁ Pasteur) is
pproved as a two-dose schedule in children aged 9–23 months. For
hildren aged <2 years, both MenACWY-CRM197 and MenACWY-DT
re recommended for use in those with complement deﬁciencies or
xposure due to travel/residence in an endemic area and, in addi-
ion, MenACWY-CRM197 is recommended in those with asplenia
ncluding sickle cell disease [17,18].
GlaxoSmithKline Vaccines’ MenACWY vaccine with all
erogroups conjugated to tetanus toxoid (TT) (MenACWY-TT:
imenrixTM), is licensed as a single dose in Europe, but remains
nvestigational in the US. One dose of MenACWY-TT is immuno-
enic and well tolerated in children from 12 months of age,
dolescents and adults [19–26].
We investigated the safety and immunogenicity of MenACWY-
T when given as a booster dose for the C/Y antigens, and as
 priming dose for the A/W antigens in toddlers 12–18 months
f age who were primed with HibMenCY-TT and combined
iphtheria–tetanus–acellular pertussis–hepatitis B and inactivated
oliomyelitis vaccine (DTaP–HBV–IPV). The study also evaluated
he co-administration of DTaP with MenACWY-TT (reported in
27]).
. Methods
.1. Study designThis Phase III, randomized, controlled study was  conducted in
9 US centers between 09 December 2008 and 19 August 2010. The
tudy protocol was approved by local or central ethics committees
or each center. The study was conducted in accordance with Goodhed  by Elsevier  Ltd. This  is  an  open  access  article  under  the  CC BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Clinical Practice and the Declaration of Helsinki (1996 Somerset
West). Written informed consent was obtained from each subject’s
parent/guardian prior to enrollment.
Healthy infants were enrolled and randomized 5:1 to vac-
cination at 2, 4 and 6 months of age with HibMenCY-TT and
DTaP–HBV–IPV, or Hib-TT + DTaP–HBV–IPV (Table 1, Fig. 1). At
12–15 months of age (fourth dose phase), children vaccinated
with HibMenCY-TT + DTaP–HBV–IPV were re-randomized (2:2:1)
to receive MenACWY-TT at 12–15 months of age followed by
DTaP at 15–18 months (MenACWY-TT group); MenACWY-TT co-
administered with DTaP at 15–18 months of age (Coad group); or
HibMenCY-TT at 12–15 months of age followed by DTaP at 15–18
months (HibMenCY-TT group). Hib-TT + DTaP–HBV–IPV-primed
children were not re-randomized and received DTaP at 15–18
months of age (control group). Subjects in the Coad, MenACWY-TT
and control groups did not receive Hib booster vaccination because
of an ongoing shortage of Hib conjugate vaccine in the US at the
time of study conduct [28]. The study was  conducted prior to the
availability of a meningococcal conjugate vaccine licensed in the US
for use in children <2 years of age; therefore the control group did
not receive meningococcal vaccination during the study. All sub-
jects were permitted to receive routine vaccines recommended by
ACIP.
The study was  single-blind in the primary phase due to the
different appearance of the vaccines. Prior to the fourth dose par-
ents/guardians were informed of their primary vaccination group.
Parents/guardians were aware of their treatment group in the
fourth dose phase, due to the differing number of vaccines and
serum sampling time points for the various treatment groups.
A randomization list was  used to number the vaccines. Random
assignment of the subjects for each study phase was performed
using a central, web-based system which included a minimization
procedure to ensure balanced allocation between groups at indi-
vidual centers.
2.2. Study subjects and vaccines
Participants were healthy infants between 6 and 12 weeks of
age, born after at least 36 weeks of gestation. Exclusion criteria
included prior receipt of any blood product since birth or receipt
of vaccines other than pneumococcal conjugate vaccine or human
rotavirus vaccine within 30 days of dose-1. A birth dose of hepatitis
B vaccine was allowed. A history of disease due to N. meningitidis,
Hib, diphtheria, tetanus, pertussis, hepatitis B, or polio, or vaccina-
tion against any of these diseases performed outside of the study
resulted in exclusion from both phases. Subjects included in the
fourth dose phase were to have received all three primary vaccina-
tion doses.
One 0.5 ml  dose of HibMenCY-TT contained 2.5 g of Hib polyri-
bosylribitol phosphate conjugated to TT, and 5 g each of MenC
polysaccharide and MenY polysaccharide conjugated to TT. One
0.5 ml  dose of MenACWY-TT contained 5 g of each meningococ-
cal serogroup A/C/W and Y polysaccharide conjugated to TT. The
lyophilized meningococcal vaccines were reconstituted with ster-
ile saline for injection, and were administered intramuscularly into
the left thigh or arm.
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Table  1
Study design.
Group name Primary phase
vaccinationa
Fourth dose phase vaccinationa
(Visits 1–4) 12–15 months
(Visit 4)
1 month post
vaccination
(Visit 5)
15–18 months (Visit 6) 1 month post
vaccination
(Visit 7)
2, 4, 6 months Vaccination Blood sampling Blood sampling Vaccination Blood sampling
MenACWY-TT HibMenCY-TT + DTaP-HBV-IPV MenACWY-TT Yes – DTaP Yes
HibMenCY-TT HibMenCY-TT + DTaP-HBV-IPV HibMenCY-TT Yes – DTaP Yes
Coad  HibMenCY-TT + DTaP-HBV-IPV No vaccination – Yes MenACWY-TT + DTaP Yes
Control Hib-TT + DTaP-HBV-IPV No vaccination – – DTaP Yes
Shaded areas indicate vaccination and blood sampling time points discussed in the present report.
a All subjects were permitted to receive routine vaccines recommended by the Advisory Committee on Immunization Practices. For measles, mumps, rubella, varicella,
hepatitis A and Hib vaccines, vaccination was to occur ≥30 days before or after administration of study vaccines. A shortage of Hib  conjugate vaccine in the US at the time of
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he  highest risk of invasive Hib disease. In compliance with this recommendation, 
ther groups were to receive the fourth dose of Hib conjugate vaccine when the sh
The composition of the licensed DTaP–HBV–IPV (PediarixTM,
laxoSmithKline Vaccines) and Hib-TT (ActHIBTM, Sanoﬁ Pasteur)
accines is described elsewhere [12]. The composition of DTaP
InfanrixTM, GlaxoSmithKline Vaccines) is the same as the DTaP
omponent of DTaP–HBV–IPV..3. Study objectives
The primary objectives were assessed hierarchically; that
s, an objective could only be considered formally met  after
ig. 1. Subject ﬂow through the study. See Supplementary Table 1 for details of the reaso
o  protocol immunogenicity cohort during the fourth dose phase. * Subjects did not parti
ere  lost to follow up (n = 47); or were not eligible to participate (n = 78). ** Two  subjects
ue  to lack of clarity in their vaccination status at the time the cohorts were deﬁned.low Hib conjugate vaccine to be preferentially administered to infants, who  are at
osters were not administered to anyone except those in the HibMenCY-TT group.
 was resolved.
all previous objectives were met  (see Table 2 for objectives
hierarchy).
In brief, the primary objectives were (a) to demonstrate the non-
inferiority of MenACWY-TT with and without co-administration of
DTaP to a fourth dose of HibMenCY-TT in terms of the percentage of
subjects with serum bactericidal activity (using a human comple-
ment source: hSBA) titers ≥1:8 and geometric mean titers (GMTs)
for serogroups C/Y; (b) to demonstrate the immunogenicity of a
single dose of MenACWY-TT with or without co-administration of
DTaP in terms of the percentage of subjects with hSBA titers ≥1:8 for
ns why subjects withdrew from the study or were eliminated from the according
cipate in the fourth dose Phase because they were unwilling to participate (n = 83);
 were erroneously excluded from the analysis population of the fourth dose phase
936 M. Leonardi et al. / Vaccine 33 (2015) 933–941
Table 2
Results of the inferential analysis for meningococcal antigens administered at 12–15 or 15–18 months of age (primary objectives: according-to-protocol immunogenicity
cohort, fourth dose phase).
Hierarchy Objective Endpoint Criterion Serogroup Value [95% CI] Criterion met?a
1a Non-inferiority
MenACWY-TT vs
HibMenCY-TT
hSBA titers
≥1:8
LL of 2-sided 95% CI for
difference
(MenACWY-TT –
HibMenCY-TT) is
≥−10%
C 0.0 [−1.33; 2.42] Yes
Y  0.0 [−1.31; 2.39] Yes
1b  Immunogenicity of
MenACWY-TT
hSBA titers
≥1:8
LL of 2-sided 95% CI is
≥80%
A 98.8 [96.6; 99.8] Yes
W  98.9 [96.8; 99.8] Yes
2a  Non-inferiority Coad vs
HibMenCY-TT
hSBA titers
≥1:8
LL of 2-sided 95% CI for
difference
(Coad-HibMenCY-TT)
is ≥−10%
C 0.0 [−1.30; 2.42] Yes
Y  0.0 [−1.25; 2.39] Yes
2b  Immunogenicity of
MenACWY-TT + DTaP
hSBA titers
≥1:8
LL of 2-sided 95% CI
(Coad group) is ≥80%
A 96.1 [93.0; 98.1] Yes
W  98.6 [96.4; 99.6] Yes
3  & 4 Non-inferiority of DTaP
co-administered with
MenACWY-TT vs DTaP
administration alone in
terms of the percentage of
subjects with
anti-diphtheria and
anti-tetanus antibody
concentrations ≥1.0 IU/ml
and anti-pertussis
geometric mean
concentrations [27]
5a Non-inferiority
MenACWY-TT vs
HibMenCY-TT
hSBA GMT  ratio LL of 95% CI for ratio
(MenACWY/HibMenCY-
TT) is
≥0.5
C 1.44 [1.11; 1.87] Yes*
Y 2.16 [1.71; 2.71] Yes*
5b Non-inferiority Coad vs
HibMenCY-TT
hSBA GMT  ratio LL of 2-sided 95% CI for
ratio
(Coad/HibMenCY-TT) is
≥0.5
C 2.70 [2.08; 3.50] Yes*
Y 3.36 [2.72; 4.15] Yes*
95% CI, 95 percent conﬁdence interval; LL, lower limit of the 95% CI; GMT, geometric mean antibody titer.
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pThe primary objectives were concluded in a hierarchical manner. One of the n
reported elsewhere) was not met. Therefore for subsequent objectives (indicated a
riterion  was met.
erogroups A/W; and (c) to demonstrate the non-inferiority of DTaP
o-administered with MenACWY-TT versus DTaP administration
lone in terms of the percentage of subjects with anti-diphtheria
nd anti-tetanus antibody concentrations ≥1.0 IU/ml and anti-
ertussis geometric mean concentrations. In order to meet all
rimary objectives with at least 80% power, 1548 subjects were
o be enrolled.
This paper describes the meningococcal endpoints accord-
ng to the pre-deﬁned statistical criteria summarized in Table 2.
he endpoints related to the DTaP booster vaccine are reported
n [27].
.4. Immunogenicity assessment
Blood samples were collected from subjects one month after
accination (Table 1) and prior to vaccination in the Coad group at
5–18 months of age (to assess hSBA persistence at 15–18 months
f age after three-dose infant vaccination with HibMenCY-TT). The
SBA assay was conducted as previously described [29]. A cut-off
f 1:4 is considered a correlate of protection for hSBA-MenC [30],
nd is commonly extended to other vaccine serogroups. We  con-
idered the more conservative hSBA cut-off of 1:8 as indicative of
rotection.feriority criteria for co-administration objectives related to pertussis vaccination
by *), non-inferiority could not be concluded as met even though the pre-speciﬁed
2.5. Safety and reactogenicity assessment
Speciﬁc local and general symptoms were recorded by parents
on diary cards for 8 days (Day 0–7) after the fourth dose vacci-
nation. All other adverse events (AEs) were recorded for 31 days
after vaccination. Serious AEs (SAEs) and the occurrence of spe-
ciﬁc AEs indicating new onset of chronic illness, and conditions
prompting visits to the emergency room (ER) were reported from
dose 1 until 6 months after the last vaccination via standardized
telephone script. The occurrence of rashes was recorded during the
fourth dose phase. An SAE was  deﬁned as an event resulting in death
or that was life-threatening; required hospitalization or prolonged
existing hospitalization; resulted in disability or incapacity of the
subject; or any other event considered serious by the investigator.
2.6. Statistical analyses
The analysis of immunogenicity was conducted on the
according-to-protocol (ATP) immunogenicity cohort that included
all vaccinated subjects who  complied with protocol-deﬁned proce-
dures.
Collection of a pre-vaccination blood sample in the Coad group
(Table 1) allowed calculation of vaccine response rates and GMT
ratios before and after vaccination in this group. A vaccine response
accine 33 (2015) 933–941 937
w
s
a
e
i
o
f
a
w
w
c
i
g
I
3
3
p
a
a
r
d
i
M
d
s
b
d
c
i
t
t
g
a
3
f
i
s
c
D
G
s
i
c
m
m
1
w
p
a
a
t
p
T
Table 3
Vaccine response to hSBA antibodies one month after the last vaccination in the
Coad group (according-to-protocol immunogenicity cohort, fourth dose phase).
Serogroup Pre-vaccination
status
N Vaccine response
n % [95% CI]
A S− 207 199 96.1 [92.5; 98.3]
S+  11 10 90.9 [58.7; 99.8]
Total 218 209 95.9 [92.3; 98.1]
C S−  25 25 100 [86.3; 100]
S+ 237 235 99.2 [97.0; 99.9]
Total 262 260 99.2 [97.3; 99.9]
W S− 128 125 97.7 [93.3; 99.5]
S+  94 92 97.9 [92.5; 99.7]
Total 222 217 97.7 [94.8; 99.3]
Y S−  10 10 100 [69.2; 100]
S+ 258 255 98.8 [96.6; 99.8]
Total 268 265 98.9 [96.8; 99.8]
S− = seronegative subjects (antibody titer < 1:4) prior to vaccination.
S+  = seropositive subjects (antibody titer ≥ 1:4) prior to vaccination.
Total = subjects either seropositive or seronegative at pre-vaccination.
Vaccine response deﬁned as: for initially seronegative subjects: antibody titer ≥ 1:8
after vaccination.
For initially seropositive subjects: antibody titer after vaccination ≥4 fold the pre-
vaccination antibody titer.
N  = number of subjects with both pre- and post-vaccination results available.M. Leonardi et al. / V
as deﬁned as an antibody titer ≥1:8 post-vaccination in initially
eronegative subjects, and a ≥4-fold increase in the pre-vaccination
ntibody titer in initially seropositive subjects.
Potential differences between groups were highlighted in
xploratory analyses if the asymptotic standardized 95% conﬁdence
nterval (CI) for the difference between two groups in percentages
f subjects reaching speciﬁed cutoffs excluded 0, or if the 95% CI
or the GMT  ratio between groups excluded 1. These exploratory
nalyses should be interpreted with caution considering that there
as no adjustment for multiplicity and that non-inferiority margins
ere not taken into account in these comparisons.
The analysis of safety was performed on the total vaccinated
ohort that included all vaccinated subjects. The incidence and
ntensity of symptoms were calculated with exact 95% CI for each
roup.
Analyses were performed using SAS® software 9.1 (SAS Institute
nc., Cary, NC, United States) and ProcStatXact 7.0.
. Results
.1. Study subjects
A total of 1554 subjects were enrolled and vaccinated in the
rimary vaccination phase, of which 1305 toddlers were enrolled
nd vaccinated in the fourth dose phase and 1303 included in the
nalysis (Fig. 1). The number of children enrolled at each center
anged between 2 and 75. A summary of the reasons subjects with-
rew from the study or were eliminated from the ATP cohorts
s given in Supplementary Table 1. Two subjects, one from the
enACWY-TT group and one from the HibMenCY-TT group, with-
rew during the fourth dose vaccination phase due to an AE. Both
ubjects experienced a febrile convulsion prior to the scheduled
ooster dose of DTaP (onset 38 days and 43 days after the fourth
ose of study vaccines). Neither event was considered to be vac-
ine related by the investigator. There were 955 subjects in the ATP
mmunogenicity cohort. There were more males than females in
he Coad group (165 versus 138, respectively) and more females
han males in the Control group (97 versus 78, respectively). Study
roups were otherwise comparable in terms of demographic char-
cteristics (Supplementary Table 2).
.2. Immunogenicity
The pre-deﬁned criteria (with/without DTaP co-administration)
or MenACWY-TT immunogenicity (serogroups A/W) and non-
nferiority (serogroups C/Y) with respect to the percentages of
ubjects with hSBA titers ≥1:8 were met  (Table 2). The pre-deﬁned
riteria for non-inferiority between MenACWY-TT (with/without
TaP co-administration) and HibMenCY-TT with respect to hSBA
MTs for serogroups C/Y were also met, but no statistical conclu-
ions can be drawn because one of the previous DTaP hypotheses
n the hierarchy of objectives was not met  [27]. However clinical
onclusions can be drawn regarding the immunogenicity of the
eningococcal components of the vaccine (see Section 4).
After vaccination with HibMenCY-TT or MenACWY-TT at 12–15
onths of age or with MenACWY-TT + DTaP at 15–18 months of age,
00% of subjects had hSBA titers ≥1:8 for serogroups C/Y (Fig. 2A),
hich were serogroups against which they had been previously
rimed. At least 96.1% of subjects vaccinated with MenACWY-TT
lso had hSBA titers ≥1:8 for serogroups A/W, pre-deﬁned criteria
re met. Very few subjects (≤7.8%) in the Control group had hSBA
iters ≥1:8 for any vaccine serogroup.
Exploratory analyses suggested statistically signiﬁcant higher
ost-vaccination GMTs: (1) for serogroups C/Y in the MenACWY-
T and Coad groups compared to the HibMenCY-TT group; althoughn/% = number/percentage of responders.
95% CI = exact 95% conﬁdence interval.
the difference might not be clinically relevant in MenACWY-TT
compared to HibMenCY-TT group as the lower limit of the GMTs
ratio is lower than a twofold change (see Table 2); (2) for serogroups
C/W and Y in the Coad group compared to the MenACWY-TT group;
although the difference might not be clinically relevant as the lower
limit of the GMTs ratio is lower than a twofold change (Fig. 2B).
The percentage of subjects in the Coad group with a vaccine
response was at least 95.9% for each vaccine serogroup (Table 3). At
least 96.1% of initially seronegative subjects had a vaccine response
against one or more serogroups.
Prior to vaccination in the Coad group, 89.9% and 96.3% of
subjects maintained seroprotective hSBA titers (≥1:8) against
serogroups C/Y following three-dose priming with HibMenCY-TT.
In the Coad group, GMTs increased from pre- to post-vaccination
by 107-fold for serogroup C and 53-fold for serogroup Y, indica-
tive of a booster response following HibMenCY-TT priming; and
by 44-fold for serogroup A and 244-fold for serogroup W,  show-
ing good immunogenicity to the ﬁrst exposure to these vaccine
antigens (Supplementary Table 3). Vaccine response rates and fold
increases in hSBA GMTs could not be calculated in the MenACWY-
TT group since the study design did not include a pre-booster blood
draw for this cohort (Table 1).
Post-dose-4 seroprotection rates and GMTs to serogroup W
were high in the MenACWY-TT and Coad groups, as well as in
HibMenCY-TT recipients who did not receive the W vaccine antigen
at dose 4. No response to serogroup W was observed in controls.
3.3. Reactogenicity
The percentages of subjects reporting local and general symp-
toms were similar in the three investigational groups (Fig. 3). The
percentages of subjects reporting SAEs, new onset of chronic dis-
ease and AEs resulting in an ER visit from the onset of primary
vaccination until 6 months after the fourth dose were similar across
the three groups (Table 4). Three SAEs reported in two subjects
were considered to be vaccine-related: there was  one case of a
ﬂoppy infant that occurred 47 days post-dose-4 (Coad group),
which resolved after 2 days. In addition, there was  one reported
case of convulsion that occurred 65 days after the ﬁrst primary
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Fig. 2. Percentage of subjects with (A) hSBA titers ≥1:8 and (B) hSBA GMTs one month after vaccination with MenACWY-TT or HibMenCY-TT at 12–15 months of age,
with  MenACWY-TT + DTaP at 15–18 months of age or with DTaP at 15–18 months of age (control group) (ATP immunogenicity cohort, fourth dose phase). ATP = according
to  protocol; hSBA = serum bactericidal activity using human complement source; GMT  = geometric mean titer. Red asterisk = statistically signiﬁcant differences observed
between the Coad group and the MenACWY-TT groups (exploratory analysis) with respect to all serogroups. Black asterisk = statistically signiﬁcant differences observed
between the indicated groups and the HibMenCY-TT group (exploratory analysis) with respect to MenC and MenY. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
Fig. 3. Local and general solicited symptoms within 8 days after vaccination with MenACWY-TT or HibMenCY-TT at 12–15 months of age, or of DTaP and MenACWY-TT
(Coad  group) at 15–18 months of age (total vaccinated cohort, fourth dose phase). For all groups, local symptoms refer to the percentage of subjects with at least one
local  symptom at the MenACWY-TT or HibMenCY-TT injection site. Any fever (any route) ≥38.0 ◦C; Grade 3: Redness and swelling >30 mm;  Pain – cried when limb was
touched/spontaneously painful; Fever (any route) >40 ◦C; irritability/fussiness and drowsiness – prevented normal activity; loss of appetite – not eating at all.
M. Leonardi et al. / Vaccine 33 (2015) 933–941 939
Table  4
Percentage of subjects reporting speciﬁc adverse events from dose 1 up to 6 months after the fourth dose (fourth dose total vaccinated cohort, primary and fourth dose
phases).
MenACWY-TT
N = 432
HibMenCY-TT
N = 229
Coad
N = 409
Control
N = 233
n % (95% CI) n % (95% CI) n % (95% CI) n % (95% CI)
At least one symptom 245 56.7 (51.9; 61.4) 140 61.1 (54.5; 67.5) 226 55.3 (50.3; 60.1) 105 45.1 (38.6; 51.7)
SAE  30 6.9 (4.7; 9.8) 11 4.8 (2.4; 8.4) 26 6.4 (4.2; 9.2) 10 4.3 (2.1; 7.8)
New  onset chronic illness 67 15.5 (12.2; 19.3) 29 12.7 (8.6; 17.7) 66 16.1 (12.7; 20.1) 36 15.5 (11.1; 20.7)
Drug  hypersensitivity 12 2.8 (1.4; 4.8) 7 3.1 (1.2; 6.2) 9 2.2 (1.0; 4.1) 5 2.1 (0.7; 4.9)
Food  allergy 5 1.2 (0.4; 2.7) 1 0.4 (0.0; 2.4) 2 0.5 (0.1; 1.8) 2 0.9 (0.1; 3.1)
Hypersensitivity 2 0.5 (0.1; 1.7) 0 0.0 (0.0; 1.6) 0 0.0 (0.0; 0.9) 1 0.4 (0.0; 2.4)
Milk  allergy 1 0.2 (0.0; 1.3) 0 0.0 (0.0; 1.6) 2 0.5 (0.1; 1.8) 1 0.4 (0.0; 2.4)
Multiple allergies 2 0.5 (0.1; 1.7) 1 0.4 (0.0; 2.4) 2 0.5 (0.1; 1.8) 0 0.0 (0.0; 1.6)
Seasonal allergy 3 0.7 (0.1; 2.0) 2 0.9 (0.1; 3.1) 2 0.5 (0.1; 1.8) 4 1.7 (0.5; 4.3)
Selective IgA immunodeﬁciency 0 0.0 (0.0; 0.9) 0 0.0 (0.0; 1.6) 1 0.2 (0.0; 1.4) 0 0.0 (0.0; 1.6)
Hypotonia 0 0.0 (0.0; 0.9) 0 0.0 (0.0; 1.6) 0 0.0 (0.0; 0.9) 1 0.4 (0.0; 2.4)
Asthma  11 2.5 (1.3; 4.5) 2 0.9 (0.1; 3.1) 7 1.7 (0.7; 3.5) 3 1.3 (0.3; 3.7)
Bronchial hyperreactivity 10 2.3 (1.1; 4.2) 4 1.7 (0.5; 4.4) 12 2.9 (1.5; 5.1) 5 2.1 (0.7; 4.9)
Rhinitis  allergic 4 0.9 (0.3; 2.4) 4 1.7 (0.5; 4.4) 6 1.5 (0.5; 3.2) 7 3.0 (1.2; 6.1)
Alopecia areata 0 0.0 (0.0; 0.9) 1 0.4 (0.0; 2.4) 0 0.0 (0.0; 0.9) 0 0.0 (0.0; 1.6)
Dermatitis allergic 3 0.7 (0.1; 2.0) 1 0.4 (0.0; 2.4) 0 0.0 (0.0; 0.9) 1 0.4 (0.0; 2.4)
Dermatitis atopic 5 1.2 (0.4; 2.7) 0 0.0 (0.0; 1.6) 10 2.4 (1.2; 4.5) 2 0.9 (0.1; 3.1)
Dermatitis contact 3 0.7 (0.1; 2.0) 1 0.4 (0.0; 2.4) 3 0.7 (0.2; 2.1) 1 0.4 (0.0; 2.4)
Drug  eruption 1 0.2 (0.0; 1.3) 0 0.0 (0.0; 1.6) 0 0.0 (0.0; 0.9) 0 0.0 (0.0; 1.6)
Eczema 16 3.7 (2.1; 5.9) 7 3.1 (1.2; 6.2) 18 4.4 (2.6; 6.9) 6 2.6 (1.0; 5.5)
Rash  1 0.2 (0.0; 1.3) 0 0.0 (0.0; 1.6) 0 0.0 (0.0; 0.9) 0 0.0 (0.0; 1.6)
Rasha 120 27.8 (23.6; 32.3) 64 27.9 (22.2; 34.2) 106 25.9 (21.7; 30.5) 48 20.6 (15.6; 26.4)
Emergency room visit 145 33.6 (29.1; 38.2) 92 40.2 (33.8; 46.8) 145 35.5 (30.8; 40.3) 57 24.5 (19.1; 30.5)
N = number of subjects with at least one administered dose.
n/% = number/percentage of subjects reporting the symptom at least once.
95% CI = exact 95% conﬁdence interval; LL = lower limit, UL = upper limit.
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a From the fourth dose until 6 months after the fourth dose.
accination dose (HibMenCY-TT group) that resolved in an infant
ho later died of a second SAE (sudden infant death syndrome) 89
ays post-dose-1. There were three other deaths during the study
all in the primary phase), none of which were considered to be vac-
ine related: one subject died from sudden infant death syndrome
3 days post-dose-1; one subject from dehydration, hemolytic
remic syndrome and septic shock 43 days post-dose-1, and one
ubject from leukemia (onset 57 days post-dose-3) and eventual
espiratory failure.
. Discussion
A single dose of MenACWY-TT during the second year of life
ollowing three doses of HibMenCY-TT at 2, 4 and 6 months
f age induced robust immune responses to all four meningo-
occal vaccine antigens, regardless of whether or not DTaP was
o-administered. Fourth dose vaccination with HibMenCY-TT also
nduced robust immune responses against serogroups C/Y. High
accine response rates and fold-increases in GMTs observed in the
oad group are evidence of effective priming for the C and Y anti-
ens with HibMenCY-TT.
The study objectives relating to hSBA titers ≥1:8 for MenACWY-
T immunogenicity (with and without DTaP co-administration)
ere successfully met  for all four serogroups. All pre-speciﬁed
riteria for non-inferiority between MenACWY-TT and HibMenCY-
T, and between MenACWY-TT + DTaP and HibMenCY-TT were met,
ven though the non-inferiority objectives cannot all be formally
oncluded due to the hierarchical statistical analysis testing strat-
gy. All subjects who received MenACWY-TT or HibMenCY-TT in
he second year of life had hSBA titers associated with seroprotec-
ion for serogroups C/Y, suggesting that both vaccines will afford
imilar protection against serogroups C/Y in HibMenCY-TT-primed
hildren.mary System Organ Class).
Exploratory analyses suggested statistically signiﬁcantly higher
GMTs in the Coad and MenACWY-TT groups compared to the
HibMenCY-TT group for serogroup C/Y, suggesting an enhancing
effect possibly due to the additional TT contained in MenACWY-TT
(approximately 44 g TT versus 18 g TT in HibMenCY-TT), even
though the lower limit of the GMTs ratio between MenACWY-TT
and HibMenCY-TT is lower than a twofold change. Immune-
enhancing effects of conjugate vaccines using TT as carrier protein
have been consistently observed [10,31–33]. Higher rSBA GMTs
were also observed in toddlers when DTPa–HBV–IPV/Hib–TT
was co-administered with MenACWY-TT than after MenACWY-
TT alone [24]. Available evidence suggests that persisting titers
(serogroup C) are higher after a four-dose series of TT-conjugate
vaccine than after four doses of CRM197-conjugate, or three doses
of TT followed by a fourth CRM197 dose [34,35].
Subjects in the HibMenCY-TT groups showed markedly higher
seroprotection rates and GMTs to W compared to the control group,
even though neither group had previously received the W antigen.
This may  reﬂect a degree of cross-reactivity between serogroups
Y and W due to their close structural similarity [36]. The lack of
response in controls indicates that the high serogroup W responses
observed in the HibMenCY-TT group are not the result of natural
immunity or a lack of assay sensitivity.
Both MenACWY-TT (with/without co-administered DTaP)
and HibMenCY-TT had an acceptable clinical safety proﬁle in
HibMenCY-TT-primed subjects. The reactogenicity in the groups
that received MenACWY-TT did not appear to be increased as
compared to HibMenCY-TT, despite the higher TT content in
MenACWY-TT.
Potential limitations of this study include the lack of a meningo-
coccal conjugate vaccine as control, and a Hib vaccine shortage
in the US when the study was conducted which meant that the
MenACWY-TT, Coad, and control groups did not reﬂect the cur-
rent US standard of care, which hampered direct comparison of
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roups. The study was powered only for non-inferiority com-
arisons; the numerous exploratory statistical comparisons were
erformed without adjustment for multiplicity and should be inter-
reted cautiously. Blood sampling at the pre-booster time point
ould, in retrospect, have provided useful information, but was  not
one in all groups in order to reduce the number of blood draws
onsidering that the study was conducted in infants, and because a
igniﬁcant body of data exist regarding the persistence of antibod-
es from the post-dose 3 time point after Hib-MenCY-TT. Finally, the
ourth dose phase had an open design which may  have inﬂuenced
E reporting and attribution of the relationship of AEs to vaccina-
ion, but would more likely be biased against the investigational
roduct. Bias in terms of immunogenicity is unlikely, as laboratory
ersonnel were blinded to treatment group during the laboratory
nalysis.
These data provide support that MenACWY-TT can be admin-
stered as an alternative to a fourth dose of HibMenCY-TT in the
econd year of life. In such a case, the fourth Hib dose should be
dministered as either monovalent or combination Hib vaccine.
he HibMenCY-TT vaccine offers protection against meningococcal
isease due to serogroups C and Y in young infants with no need
or additional injections or visits to the current infant vaccination
chedule. Furthermore, administering MenACWY-TT as the fourth
ose offers the opportunity to broaden coverage to include the less
revalent serogroups A and W.
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